Candesartan/Hydrochlorothiazide - paediatric investigation plan

Candesartan

hydrochlorothiazide

Key facts

• Invented name:
  Blopress Comp and associated names
• Active substance:
  • Candesartan
  • hydrochlorothiazide
• Therapeutic area:
  Cardiovascular diseases
• Decision number:
  P/4/2007
• PIP number:
  Candesartan/Hydrochlorothiazide
• Pharmaceutical form(s):
  Tablet
• Condition(s) / indication(s):
  Essential hypertension
• Route(s) of administration:
  Oral use
• Decision type:
  W: decision granting a waiver in all age groups for all conditions or indications
• Decision date:
  11/12/2007
• Compliance check done:
  No

Decision

P/4/2007: European medicines agency decision of 11 December 2007 on the application for a product specific waiver for Blopress Comp and associated names, Candesartan/Hydrochlorothiazide (EMEA-000040-PIP01-07) in accordan...

Adopted Reference Number: EMEA/575788/2007